ISM1354 / Insilico Medicine - LARVOL DELTA

Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity (Drug Target Review) - "The announcement comes as researchers and drug developers explore combinations of GIPR antagonists with glucagon-like peptide-1 receptor (GLP-1R) therapies...Researchers then carried out multiple design-make-test-analyse cycles using experimental data before selecting ISM1354 as the preclinical candidate...According to Insilico, ISM1354 demonstrated consistent pharmacokinetic characteristics across mice, rats, dogs and monkeys, with oral bioavailability ranging from 75 percent to 104 percent...At the same dose level, the compound produced at least 18 times greater plasma exposure than a clinical-stage benchmark compound, which the company said supported its development potential."

Pipeline update • Preclinical • Obesity • Type 2 Diabetes Mellitus